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from Genome-wide Association Studies
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and Hakon Hakonarson1,4,5,*
GWAS have been successful in identifying disease susceptibility loci, but it remains a challenge to pinpoint the causal variants in subse-
quent ﬁne-mapping studies. A conventional ﬁne-mapping effort starts by sequencing dozens of randomly selected samples at suscepti-
bility loci to discover candidate variants, which are then placed on custom arrays or used in imputation algorithms to ﬁnd the causal
variants.We propose that one or several rare or low-frequency causal variants can hitchhike the same common tag SNP, so causal variants
may not be easily unveiled by conventional efforts. Here, we ﬁrst demonstrate that the true effect size and proportion of variance
explained by a collection of rare causal variants can be underestimated by a common tag SNP, thereby accounting for some of the
‘‘missing heritability’’ in GWAS. We then describe a case-selection approach based on phasing long-range haplotypes and sequencing
cases predicted to harbor causal variants.We compare this approachwith conventional strategies on a simulated data set, andwe demon-
strate its advantages when multiple causal variants are present. We also evaluate this approach in a GWAS on hearing loss, where the
most common causal variant has a minor allele frequency (MAF) of 1.3% in the general population and 8.2% in 329 cases. With our
case-selection approach, it is present in 88% of the 32 selected cases (MAF¼ 66%), so sequencing a subset of these cases can readily reveal
the causal allele. Our results suggest that thinking beyond common variants is essential in interpreting GWAS signals and identifying
causal variants.Introduction
GWAS have been very successful in identifying and repli-
cating disease-susceptibility loci for common and complex
human diseases.1–3 A commonly held view is that the
success of GWAS depends on the validity of the common
disease/common variant (CD/CV) hypothesis, which spec-
iﬁes that most of the genetic risk for common diseases is
due to disease loci where there is one common variant
(minor allele frequency [MAF] > 5%) with small effect
sizes.4,5 There has been a large volume of literature
debating over whether the CD/CV hypothesis describes
a large portion of the genetic susceptibility to common
and complex diseases.6–15 However, it is generally assumed
that association signals detected from GWAS represent
linkage disequilibrium (LD) between a common tag SNP
and a common causal variant with a small effect size and
therefore explain only a minor proportion of disease heri-
tability. If a common causal variant is responsible for an
association signal in GWAS, it should be straightforward
to zoom into the candidate region and identify the variant
in subsequent ﬁne-mapping studies with small sample
sizes, although common variants with subtle effects could
be difﬁcult to recognize as causal even once identiﬁed.
We have recently demonstrated that rare variants can
create synthetic association signals in GWAS, by occurring
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in which common SNPs seem to confer risk for common
diseases.16 The term ‘‘synthetic’’ does not imply that the
association is spurious, but rather that it has different prop-
erties from what is commonly assumed (i.e., that one
common causal variant underlies an association signal).
An illustration of this concept is given in Figure 1, in which
two causal variants emerge recently at the same haplotype
background of a tag SNP, so the tag SNP represents the
combined effects of both causal variants in present human
populations. A third, very rare causal variant emerges in cis
with the alternative allele of the tag SNP, so it may have
minor antagonistic effects on the association signal. In
short, the nature of genealogies presents multiple chances
to partition rare variants such that an imbalance of allele
frequencies can exist between cases and controls, and
given the abundance of ancestral common SNPs in the
genome, these differences can usually be picked by
common tag SNPs. We note that the ‘‘tag’’ measure tradi-
tionally uses r2, which favors SNPs with similar allele
frequencies (due largely to the relationship between power,
sample size, and r2), whereas we focused on theD0 measure
in the current study so as to better assess the relationship
between a common tag SNP and rare causal variants.
Extensive coalescence simulations show that such syn-
thetic associations are not only possible but also inevitable;
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Figure 1. An Illustration Comparing the
Canonical Common Disease/Common
Variants Assumption and the ‘‘Synthetic
Association’’ Theory
The left panel represents a genealogy tree
showing the emergence of causal muta-
tions and tag SNPs over human evolu-
tionary history, while the right panel
illustrates the catalog of variants within
present human populations. Under syn-
thetic association, thebest tag SNPcaptures
the combined effects of causal mutations;
additionally, since causal variants arise
recently, the tag SNP is in long-range LD
with either causal variant.multiple causal variants, each of which is likely to be rare,
then some true causal variants could lie outside of the LD
block containing the most signiﬁcant tag SNPs, and
multiple seemingly independent association signals may
be present at the same locus.16 As a corollary, resequencing
a narrow LD block at susceptibility loci in a small number
of randomly selected control samples may not reveal the
causal variants. Whole-genome imputation, even after
the completion of the 1000 Genomes Project, may not
ﬁnd the causal variants either, unless rare variants (usually
ethnicity-speciﬁc) are present in the haplotype data and
can be imputed accurately.
There are a few known examples supporting the hypoth-
esis that multiple rare variants may collectively be respon-
sible for an association signal. First, three rare variants in
NOD2 (MIM 605956) (rs2066844, rs2066845 and
rs2066847, MAF range from 1% to 5%) were found to be
associated with susceptibility to Crohn disease (MIM
266600) in 200117,18 and, on the basis of functional assays,
were potentially causal.19 Although there are no known
common causal variants inNOD2, theWellcome Trust Case
Control Consortium (WTCCC) study in 2007 implicates
a common tag SNP within NOD2 (rs17221417, MAF ¼
29%).20 In the HapMap CEU population (Utah residents
with ancestry from northern and western Europe), two
rare variants (rs2066844 and rs2066845) are in completeThe American Journal of HumanLD (D0 ¼ 1) with the tag SNP, suggest-
ing that the tag SNP may represent
the combined effects of at least two
rare variants (information for the third
rare variant is not available from
HapMap). Second, with the use of
population-wide resequencing, multi-
ple rare and ethnicity-speciﬁc muta-
tions in PCSK9 (MIM 607786) have
been associated with low-density lipo-
protein (LDL) cholesterol levels in
both EuropeanAmericans and African
Americans,21 multiple rare mutations
in ANPGTL family members are
associated with plasma triglyceride
levels,22 and multiple rare mutationsin ABCA1 (MIM 600046), APOA1 (MIM 107680), and
ANPGTL4 are associated with high-density lipoprotein
(HDL) cholesterol levels.23,24 Recent GWAS on dyslipide-
mia convincingly identiﬁed association between these
genes and the corresponding lipid traits, through the use
of common tag SNPs (rs11206510 for PCSK9, MAF ¼ 19%;
rs10889353 for ANPGTL3, MAF ¼ 33%; rs964184 for
APOA1, MAF ¼ 14%; rs1883025 for ABCA1, MAF ¼ 26%;
rs2967605 for ANPGTL4, MAF ¼ 16%).25 Third, Zhu et al.
sequenced the angiotensinogen gene and found that
multiple rare variants contribute to variation in angiotensi-
nogen levels; interestingly, most of these variants sit on the
same haplotype background created by three common
SNPs.26 Fourth, three common tag SNPs encompassing
MC1R (MIM 155555) were ‘‘independently’’ associated
with melanoma in a recent GWAS.27 However, resequenc-
ing of the candidate gene, MC1R, indicates that these
signals can be completely explained by the combined
effects of several rare nonsynonymous mutations, suggest-
ing that ‘‘ignoring rare variants can lead to incorrect
inferences on the potential role of candidate genes carrying
common SNPs identiﬁed by GWAS’’ (F. Demenais at al.
[2009]. Importance of sequencing rare variants after a
genome-wide association study (GWAS): the MC1R gene,
16q24 region and melanoma story, paper presented at
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Meeting, Honolulu, HI, USA). Fifth, many hundreds of
human leukocyte antigen (HLA) alleles and haplotypes
exist in human populations, and some of them cause auto-
immunediseases.28 Although some SNPs can tag individual
HLA alleles well,29,30 many association signals in GWAS
by diallelic SNP markers potentially represent synthetic
association, whereby one SNP allele tags multiple HLA
alleles. Sixth, we have shown that even a single rare causal
allele (MAF ¼ 3.6%) can create signiﬁcant association
signals in a GWAS for sickle cell anemia (p ¼ 1.1 3 10136
for rs7120391, MAF ¼ 11%) and that genome-wide signiﬁ-
cant (p < 5 3 108) signals can extend over 2.5 Mb across
many dozens of r2-based LD blocks visually discernable in
the HapMap population.16 The causal allele is under strong
positive selection to protect against malaria, representing
a classic example of heterozygote advantage,31 but it also
represents an example that recently emerged causal alleles
can leave a trace of long-range haplotypes surrounding
the allele. Finally, we have shown that hearing loss, with
hundreds of known causal mutations at the GJB2 ([MIM
121011])-GJB6 ([MIM 604418]) loci but without common
causal variants,32 is associated with several seemingly inde-
pendent common tag SNPs around GJB2.16 In summary,
none of these association signals on common tag SNPs
discussed above are spurious signals; instead, they may
represent scenarios whereby multiple causal variants work
together to create genome-wide signiﬁcant association
signals,which are being accredited to one common tag SNP.
Thepurposeof the current study isnot to speculateon the
fraction of association signals that can be attributed to the
presence of multiple causal alleles. Rather, our aim is to
accept the possibility that some signals in GWAS emerge
from rare causal variants, and to use this possibility to
leverage the extensive GWAS data in the search for causal
variants. On the basis of the observation of differential LD
between tag SNPs in cases compared to controls, together
with the observation of long-rangehaplotypes surrounding
tag SNPs, we present an approach for selecting cases to
maximize the chance of ﬁnding causal variants. We evalu-
ated this approach on a simulated data set and compared
it with conventional ﬁne-mapping approaches to identify
causal variants. We also tested the approach on a GWAS
onhearing loss, inwhichwe know the identity of the causal
variants, and we have sequenced all available cases for the
presence of causal variants. We believe that our theoretic
framework andour case-selectionapproachwill have signif-
icant implications for the design of follow-up studies after
a successful GWAS in order to facilitate success in ﬁnding
the causal genes and their causal variants.Material and Methods
Deﬁnition of a Synthetic Causal Marker
When more than one rare variant is present in the same gene in
a population, in order to facilitate modeling of their joint effect,
we create a synthetic marker that represents the combined effect
of several rare variants. To simplify the description below, suppose732 The American Journal of Human Genetics 86, 730–742, May 14,that there are two rare causal variants with minor (causal) allele
frequencies of pM and pN, respectively. Given that both variants
are rare and recent, and that they are physically close (within
the same gene), it is reasonable to assume that they are in
complete LD with opposite direction (that is, thatM and N alleles
never occur in cis, or that only three haplotypes are present in
population: Mn, mN and mn). Therefore, for the synthetic
marker, the genotype is heterozygous when the two homologous
chromosomes are in conﬁguration of Mn/mn or mN/mn, and
it is homozygous when the two homologous chromosomes are
in conﬁguration ofMn/mN,Mn/Mn, ormN/mN.
Let the two alleles for the synthetic marker beA as risk allele and
a as non-risk allele. The allele frequency of the synthetic marker is
the sum of M and N alleles. If the two causal variants are not in
perfect LD, that is, if the MN haplotype exists in population, we
can assume that that penetrance of anMN haplotype is identical
to that ofMn ormN, whichever is larger. If we suppose thatMn is
more penetrant than mN, then effectively we could consider
a modiﬁed second causal variant with allele frequency of pNpMN
and pnþpMN, which has complete LD with the ﬁrst causal variants.
A synthetic causal marker can then be built from these two causal
variants. Similarly, multiple causal variants can be modeled in
a stepwise fashion. In cases where causal variants are protective,
the allele frequency of the synthetic marker needs to be subtracted
by that of the protective allele.
Relationship of Allelic Odds Ratio between the
Synthetic Causal Marker and the Tag SNP
A general formula describing the allelic odds ratio (OR) for the tag
SNP (with alleles B and b), based on the OR estimated from the
synthetic causal variant (with alleles A and a), is
ORB ¼ 1þ DðORA  1Þ
pB½ð1 pBÞ þ ðpAð1 pBÞ DÞðORA  1Þ (Equation 1)
in which the allele frequency is pA< pB andD is the LD coefﬁcient.
The formula has been previously described.33
Assuming that the causal marker and the tag SNP have complete
LD with identical direction, we have D ¼ pA(1-pB). The above rela-
tionship can therefore be simpliﬁed as:
ORB  1
ORA  1 ¼
pA
pB
(Equation 2)
Relationship of the Locus-Speciﬁc Sibling Recurrence
Risk Ratio between the Synthetic Causal Marker and
the Tag SNP
The locus-speciﬁc sibling recurrence risk ratio, or lS, can be calcu-
lated as
lS ¼ 1þ ðVA=2þ VD=4Þ
K2
(Equation 3)
in which VA is the additive genetic variance, VD is the dominance
genetic variance, and K is the population prevalence of the
disease.34 Let Va ¼ VA /f02 and Vd ¼ VD /f02, in which f0 is the pene-
trance of the wild-type genotype, as shown before,35 and the
formula can be rewritten as
lS ¼ 1þ ðVa=2þ Vd=4Þð1 PARÞ2
For the causal marker with A and a alleles in which PAR is the
population attributable risk, we have:2010
Table 1. Effect Sizes of Three Causal Variants and the Tag SNP at the NOD2 Locus for Crohn Disease
SNP Function MAF GRR (Het) GRR (Hom) PAR lS
Proportion of Genetic
Risk Explaineda
Causal Variants
rs2066844 Arg702Trp 4.1% 1.71 2.73 5.55% 1.018 0.54%
rs2066845 Gly908Arg 1.5% 2.53 12.13 4.55% 1.040 1.2%
rs2066847 Leu1007fsinsC 1.9% 3.64 12.06 9.29% 1.118 3.4%
Three-SNP Combination 18.2% 1.184 5.1%
Tag SNP
rs17221417 Tag SNPb 28.7% 1.29 1.93 16.4% 1.023 0.69%
The three causal variants have a combined lS similar to that observed in linkage studies, explaining the heritability at the locus. The lS estimate based on the tag
SNP creates a false impression of ‘‘missing heritability.’’ MAF, minor allele frequency; GRR, genotype relative risk; Het, heterozygotes; Hom, homozygotes; PAR,
population attributable risk.
a The total lS for Crohn disease is estimated to be 27.2, following
50.
b rs17221417 is the tag SNP reported in Table 2 of the WTCCC paper.20 The MAF and GRR were estimated with the use of WTCCC data.VaðAÞ ¼ 2pApa

pað1GRRAaÞ þ pAðGRRAa GRRAAÞ
2
(Equation 4)
VdðAÞ ¼ p2Ap2a ½1þGRRAA  2GRRAa2 (Equation 5)
1 PARðAÞ ¼ 1
GRRAAp2A þ 2GRRAapApa þ p2a
(Equation 6)
In the study, we plot the relationships between lS for the
synthetic causal marker and the tag SNP, given prespeciﬁed values
of genotype relative risk (GRR) and a ladder of allele frequencies.
Simulation of Sequencing Data on a Susceptibility
Locus
We simulated sequencing data that mimic the scenario described
in Table 1 in order to evaluate different resequencing strategies
for identifying causal variants from a susceptibility locus detected
in GWAS when multiple causal variants are present. In the
simulation, we assumed that three causal variants with MAF
of ~1%, 2%, and 4% are present at the same locus with a GRR
of ~3. Genealogical trees were simulated with GENOME,36 with
an effective population size of 10,000 and a mutation rate of
108 used. A random gene genealogy was drawn, with mutations
distributed along the genealogy, and disease-causing mutations
were assigned at random from those variants that were within
the allowed frequency range. Two simulated haplotypes were
randomly selected with replacement for each individual, and
1000 individuals were generated, including an equal number of
cases and controls. Case or control status was designated on the
basis of the assigned risk. The simulation data sets can be down-
loaded from the website listed in the Web Resources section.
The simulation data set contains a total of 4116 segregating sites
within a 2 Mb region. To simulate genotyping data on these
subjects in a GWAS, we randomly selected SNPs so that their
MAF distribution followed a uniform distribution between 0 and
0.5. In total, 504 SNPs were selected as if they were genotyped
by a GWAS, with an average intermarker distance of ~4 kb. We
tested all variants in the hypothetical genotyping array for associ-
ation with disease status, by allelic association tests in PLINK.37
Genome-wide Search for Long-Range
Haplotypes in Cases
Because rare causal variants arose recently, they often exist on
long-range haplotypes spanning multiple blocks of high LD (asThe Ameobserved in control populations), which recombination has not
yet had a chance to further fragment. The concept of the long-
range haplotype has beenwidely used in human genetics research.
For example, it has been used for inferring positive selection from
the human genome,38,39 used in population-based linkage anal-
ysis for identifying disease-susceptibility loci,37–40 and used in
inferring the population origin of private alleles.41 In addition,
previous resequencing studies on rare variants clearly demon-
strated the presence of long-range haplotypes, suggesting that
rare causal alleles were generally recent in origin.42 Furthermore,
contrasting LD patterns in cases versus controls offers improved
power to localize some association signals.43,44 Therefore, long-
range haplotypes that are preferentially observed in cases tend
to be those that harbor rare causal alleles, and such loci will display
differences in LD structure between cases and controls.
We performed genome-wide scanning of the SNP genotype data
to identify regions likely to harbor long-range haplotypes in cases,
by contrasting LD patterns between cases and controls with the
use of index SNPs. This analysis was facilitated with the use of
the ‘‘clumping’’ function in the PLINK software.37 The clumping
procedure takes all signiﬁcant SNPs (by default p < 1 3 104) as
index SNPs and forms clumps of all nearby SNPs (by default
p < 0.01), using the ‘‘--clump-r2 0’’ argument to include all SNPs
regardless of r2 with the index SNP. Next, we compared the D0
values between the index SNP and all nearby clumped SNPs in
cases versus controls. Our rationale is that even if two SNPs are
not in LD in the control population, if two alleles in the two
SNPs happen to be in the same long-range haplotypes that were
carried through the genealogy, then greater LD should be detected
in cases that enrich for such long-range haplotypes. Thus, for
a given index SNP, we calculated the D0 with all nearby SNPs in
cases (D0case) and in controls (D0control), as well as the ratio of the
D0 measure in cases versus in controls (D0case / D0control). For each
index SNP, summary statistics can be calculated as the median of
these ratios, and a higher value indicates better correlation of adja-
cent SNPs in cases than in controls.Phasing Long-Range Haplotypes at Susceptibility Loci
Assuming that rare causal variants can be tagged by speciﬁc long-
range haplotypes, we attempted to identify a subset of tag SNPs
that are maximally informative for long-range haplotype
construction, because these tag SNPs need to differentiate the
effect of long-range haplotypes and ancestral short-range LDrican Journal of Human Genetics 86, 730–742, May 14, 2010 733
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Figure 2. Illustration of an Odds Ratio for a Tag SNP and
a Synthetic Causal Marker
The relationship between the odds ratio (OR) observed on a tag
SNP with MAF ¼ 30% and the true OR for a synthetic causal
marker is shown, with MAF ranging from 1% to 10%. In all
scenarios, the tag SNP underestimate the true effect size, especially
when the causal marker is relatively rare.blocks in the human genome. Therefore, from the ‘‘clump’’ of
SNPs at a susceptibility locus, we speciﬁcally chose SNPs that
appear to be tightly linked to the index SNP in cases versus in
controls, on the basis of D0case / D0control. In the hearing-loss data,
possibly due to the presence of onemajor risk allele, the ratio tends
to be relatively large, so we arbitrarily picked a threshold of > 2 to
select SNPs for haplotype phasing. In the simulation data, we used
a threshold of > 1.2 to select six SNPs.
We relied on the fastPHASE program45 for building long-range
haplotypes for cases and controls together, using the SNPs selected
from the previous step. All default parameters were used, and the
‘‘-i’’ option was used to minimize individual error as opposed to
switch error.
Identify Subset of Cases for Sequencing
After haplotype phasing, we aimed to identify a subset of cases to
enrich for samples who are more likely to harbor causal variants.
The best-guess haplotypes for each sample are used to assess the
frequency of each haplotype in cases and controls, and Fisher’s
exact test is used to assess whether a long-range haplotype is asso-
ciated with disease status. We acknowledge that fastPHASE does
not account for haplotype-phasing uncertainty, but it offers
greatly improved speed. Because our purpose is to enrich a subset
of cases carrying speciﬁc causal variants, some phasing errors can
be tolerated. On the basis of the hypothesis that the ﬁrst few long-
range haplotypes that are overrepresented in cases versus controls
could tag the major classes of rare causal variants, we can select
cases that carry these speciﬁc haplotypes for resequencing studies.Results
Effect Sizes May Be Underestimated in GWAS
One of the most consistent themes from analysis of GWAS
data is that, with rare exceptions, the effect sizes of the
susceptibility loci tend to be modest, with an OR typically
less than 1.3 2. Because the power of association studies
depends on effect sizes, it likely that most additional unde-
tected susceptibility loci have even smaller effect sizes.
However, if an association signal is due to the presence of
multiple rare variants, then the estimated effect sizemerely
reﬂects that assigned to the tag SNPs, which could be very
different from those of the causal variants. This possibility
has been recognized, but mainly in the context of the
assumption that the causal site is imperfectly tagged by
the common variant. The possibility that much of the
signal comes from multiple rare variants has not been
systematically addressed.
To investigate the relationships of effect sizes between
common tag SNPs and rare causal variants in a quantitative
manner, we need to create an artiﬁcial ‘‘synthetic causal
marker,’’ which represents the combined effect of one or
more causal variants. Assuming that causal variants do
not occur in cis (one variant masks the effect of another
if they do), the allele frequency of the synthetic marker is
the sum of all causal variants, whereas the effect sizes
(odds ratio and GRR) can be expressed as a weighted sum
from those of the causal variants. In the discussion below,
we treat the susceptibility locus as if there is only one
synthetic causal marker (with A as risk allele and a as734 The American Journal of Human Genetics 86, 730–742, May 14,non-risk allele), and we examine how well the tag SNP
(with B as risk allele and b as non-risk allele) represents
the effects of this synthetic causal marker. It is well known
that differences in odds ratio estimates could exist if allele
frequencies of a tag SNP differ much from a causal variant
in LD.33 This relationship is illustrated in Figure 2, by
assuming that the tag SNP has an MAF of 30% whereas
the causal marker has an MAF ranging from 1% to 10%.
In all scenarios, the tag SNP underestimates the true effect
sizes of the causal marker. For example, when the MAF ¼
1% for the causal marker, the OR of 1.2, as suggested by
the tag SNP, actually reﬂects a true OR of 7 for the causal
marker.
To demonstrate the underestimation of genetic effects
with the use of real data, we next examined the NOD2
locus for Crohn disease as an example. Three nonsynony-
mous or frameshift mutations in NOD2 were previously
associated with Crohn disease17,18 and were subsequently
conﬁrmed by many replication studies and meta-anal-
ysis.46 The three mutations have been studied by in vitro
biochemical assays and by mouse models with introduced
mutations,19 therefore conﬁrming that they play causal
roles rather than are in LD with a causal variant. A large-
scale meta-analysis on NOD2 reported estimates on allelic
OR for the three causal variants (ranging from 2.2 to
4.1),46 and a recent NOD2 genetic study has estimated
the GRR (ranging from 1.7 to 3.6 for heterozygotes)47
(Table 1). In the WTCCC study,20 the NOD2 locus was
convincingly associated with Crohn disease, through the
use of the common tag SNP rs17221417 (MAF ¼ 29%,
OR ¼ 1.37).20 Comparing the true effect size of causal vari-
ants with that inferred from rs17221417 (Table 1), it is clear
that the tag SNP severely underestimates the true effect size
of any one of the three causal variants.2010
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Figure 3. Illustration of lS for a Tag SNP and a Synthetic Causal
Marker
The relationship between lS for a tag SNPwithMAF¼ 30% and the
true lS for a synthetic causal marker is shown, with MAF ranging
from 1% to 10% (each dot represents 1% increase), under three
effect sizes with multiplicative genetic models. In all cases, the
tag SNP underestimates the familial aggregation explained by
the true causal variant.Heritability Due to Identiﬁed GWAS Loci May Be
Underestimated
A question that often arises in GWAS is ‘‘Where is the
missing heritability?’’48,49. This question refers to the fact
that the collection of variants discovered inGWAS explains
only a minor fraction of the heritability, even for diseases
or traits that are highly heritable. Multiple reasons have
been proposed to explain the missing heritability.48
However, thepresence ofmultiple rare causal variants offers
additional explanations: First, some rare causal variants
may tag the non-risk allele of a common tag SNP (see
example in Figure 1), antagonizing the effect size of the
tag SNP; similarly, a rare protective variant may tag the
risk allele of a common tag SNP, antagonizing the observed
effect size. Second, even if a tag SNP represents the
combined effects of all causal variants perfectly (D0 ¼ 1),
its heritability measure may dramatically underestimate
the true contribution of the susceptibility locus.
The theoretic foundation of differing familial risk
between a common and a rare variant, which are in com-
plete LD (D0 ¼ 1) but have different allele frequencies,
has been previously described in an excellent article by
Hemminki et al.35 Although this article serves the purpose
of explaining the discordance between population attrib-
utable risk (PAR) and familial risk, it turns out that the
statistical derivation can also be applied to an investigation
of our hypothesis. In our analysis, we considered a tag SNP
with an MAF of 30% and a causal marker with an MAF
ranging from 1% to 10% (with a 1% ladder of increase).
We then investigated the relationships of the locus-speciﬁc
lS estimates based on the tag SNP or the causal marker. The
lS represents the relative risk of siblings of patients divided
by the population prevalence of the disease, and it is used
to calculate the proportion of heritability explained by
a locus for binary phenotypes.34 We tested several effect
sizes for the causal marker by assuming multiplicative
models (Figure 3). In all cases, it is clear that the lS esti-
mates based on the tag SNP severely underestimate that
based on the causal marker, supporting previous specula-
tions that rare functional alleles could explain a much
larger proportion of familial aggregation of cases than
common tag SNPs.35
To investigate the missing heritability in real data, we
again examined the NOD2 locus in the Crohn disease
data set (Table 1). First, the PAR for the tag SNP is almost
identical to the PAR for the three causal variants combined
together (16.4% versus 18.2%), demonstrating that the tag
SNP indeed captures information from all three causal vari-
ants together. Next, using the GRR estimates,47 we calcu-
lated the locus-speciﬁc lS for the three causal variants.
Their combined effects result in a lS estimate of 1.184,
which is quite close to the estimate of lS ¼ 1.3 for NOD2
observed in linkage study.18 Therefore, two-thirds of the
familial risk at NOD2 can be explained by these three
causal variants. In fact, assuming a total lS of 27.2 for
Crohn disease (weighted estimate frommultiple studies50),
the three causal variants explain> 5% of the genetic risk ofThe AmeCrohn disease, suggesting that NOD2 is a major disease
locus. Examination of the tag SNP rs17221417 reported
by WTCCC20 reveals a locus-speciﬁc lS estimate of merely
1.023, which is not even remotely close to the expected
value of 1.3. Therefore, the tag SNP creates the false impres-
sion that the association signal explains a tiny fraction of
the linkage signal at NOD2 and that some major-effect
causal variants cannot be tagged by rs17221417. In other
words, the tag SNP creates a scenario of ‘‘missing herita-
bility,’’ in which the strongest Crohn disease-susceptibility
locus,NOD2, explains only ~1% of the total genetic risk for
Crohn disease, if we simply take the GWAS results at face
value. Altogether, extending previous studies, our analysis
suggests that the ‘‘missing heritability’’ observed in GWAS
may not be as severe as it appeared to be, if multiple rare
variants are responsible for at least a proportion of the
discovered susceptibility loci.
Comparative Strategies for Identifying Causal
Variants in a Simulated Data Set
After a successful GWAS, the next natural extension is to
ﬁne-map thediscovered susceptibility loci to identify causal
variants. Researchers may sequence a few dozen subjects
on the entire HapMap r2-based LD block harboring the
most signiﬁcantly associated SNPs, identify all common
and rare variants in these subjects, then design a custom
ﬁne-mapping panel with all of these variants to examine
a large number of cases and controls. We note that these
approaches have already been adopted formultiple diseases
by many groups (for example, see P. Deloukas andWTCCC
[2008], High throughput approaches to ﬁne mapping in
regions of conﬁrmed association, paper presented at 58th
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Philadelphia, PA, USA). However, as of today, these types
of efforts have not identiﬁed ‘‘smoking gun’’ mutations
(O. Harismendy et al. [2009], Population resequencing
and functional annotation of the 9p21 interval associated
with coronary artery disease and type 2 diabetes, paper pre-
sented at The Biology of Genomes, Cold SpringHarbor, NY,
USA; G. McVean and WTCCC [2009], Targeted resequenc-
ing and ﬁne-mapping of variants in association studies,
paper presented at The Biology of Genomes. Cold Spring
Harbor, NY, USA).51 This could be due to the insufﬁcient
power for identifying the ‘‘needle’’ from a haystack of
common variants with very similar association statistics,
or it could be due to the properties of synthetic associations.
If multiple rare variants exist, then we would expect the
following: (1) causal variantsmay fall outsideof the r2-based
LD block naturally observed in control subjects; (2) some
causal variants may not be observed in selected subjects
and therefore may not be designed on the custom arrays;
and (3) some causal variants may be on the custom arrays,
but their test statistics (p values) may not be as signiﬁcant
as commontagSNPs that representmultiple causal variants.
To examine the effectiveness of conventional approaches
for pinpointing causal variants when multiple causal
variants exist, we analyzed a simulated data set with geno-
types for a disease locus in 1000 subjects (500 cases and
500 controls). The locus contains three causal variants
with a MAF of ~1%, ~2%, and ~4% and a GRR of ~3. We
simulated genotypes for 4116 segregating sites in a 2 Mb
region by a coalescence model, and we then randomly
selected 504 SNPs with MAF following a uniform distribu-
tion between 0 and 0.5, as if there are 504 SNPs in a hypo-
thetical genotyping array for this region. The most signiﬁ-
cantly associated SNP (SNP2276) is a common tag SNP
with p ¼ 1.1 3 1010 and a MAF of 28% in cases and 16%
in controls.
From the simulation data, we evaluated a conventional
strategy of selecting a random set of 30 controls for the
identiﬁcation of variants by sequencing. We performed
1000 replicate experiments, and we found that 397, 500,
and 73 of these experiments were able to include one,
two, and three causal variants from the 30 subjects, respec-
tively. Therefore, this experimental design is unlikely to
lead to the discovery of all three causal variants to be
placed in custom ﬁne-mapping arrays. Furthermore, even
under the assumption that all three causal variants are
indeed on the ﬁne-mapping arrays, we then examined
their association statistics by comparing cases versus
controls: their p values are 2.3 3 104, 2.0 3 108 and
1.0 3 1010, respectively. However, in the entire simula-
tion data set, there is also a common variant, SNP 2034,
with p ¼ 8.8 3 1012, which completely tags all three
causal variants (D0 ¼ 1). Because most researchers assume
the existence of one common causal variant, they would
usually consider only the most signiﬁcant p value in
a region in ﬁne-mapping studies, so these causal SNPs
would be missed. Finally, we examined the role of condi-
tional regression analysis, by including SNP 2034 as cova-736 The American Journal of Human Genetics 86, 730–742, May 14,riate in a logistic regression model and assessing associa-
tion of all other variants. Although all three causal
variants show some levels of residual association, only
one of them ranks at the top of the list. Therefore, even
by conditional regression analysis, we still cannot identify
all three true causal variants. On the basis of our experi-
ments above, ifmultiple causal variants do exist at a suscep-
tibility locus, the traditional ﬁne-mapping approaches are
unlikely to identify all of them.
To address this issue and to improve the likelihood of
success, we propose a case-selection approach based on
examining long-range haplotypes, which are haplotypes
expected to contain recently emerged causal alleles. The
rationale is that resequencing studies must be focused on
subjects who are more likely to carry causal alleles, in order
to ensure a reasonably good chance of identifying these
variants for the design of ﬁne-mapping panels. We treated
SNP2276 (the most signiﬁcant SNP in the hypothetical
genotyping array) as an index SNP and identiﬁed ﬁve addi-
tional SNPs, which have higher D0 with the index SNP in
cases versus controls. Interestingly, these SNPs range
from 241 kb to the left of to 207 kb to the right of the index
SNP. We then phased all cases and controls and identiﬁed
a few haplotypes that appear to have higher frequency in
cases versus controls. Strikingly, 96/100, 59/112, and
21/36 subjects carrying the ﬁrst, second, and third haplo-
types do carry each of the three causal variants, respec-
tively. Therefore, the presence of long-range haplotypes
improves the prediction of the carrier status of the causal
variants, although it is not perfect. In any case, the selec-
tion procedure resulted in high enrichment of subjects
for each of the three causal variants, potentially facilitating
the discovery of these variants and subsequent ﬁne-
mapping efforts by custom arrays.
To further examine how the long-range haplotype-based
method works, we performed additional experiments by
constructing local haplotypes. We used PLINK37 to esti-
mate haplotype blocks for SNPs on the hypothetical geno-
typing array, and we identiﬁed an LD block with four
SNPs encompassing SNP2276. We then followed the same
procedure described above to identify haplotypes associ-
ated with disease, but only one haplotype showed higher
frequency in cases than in controls. This haplotype is
carried by 235 cases, including 98, 23, and 68 subjects with
the three causal variants, respectively. Therefore, compared
to long-range haplotypes, SNPs within a local LD block per-
formed less well in enriching subjects with speciﬁc causal
variants.
Case-Selection Approach Identiﬁes Causal Variants
in a Real Data Set
Next, we used a real GWAS data set on hearing loss to test
the case-selection method based on long-range haplo-
types. Hearing loss represents an extreme example because
of the existence of a major-effect locus near GJB2-GJB652
(similar to the MHC region for type 1 diabetes [MIM
222100]), making it different from many other complex2010
Table 2. A List of SNPs that Are Associated with Hearing Loss with p < 0.01 and Are within 1 Mb from the Index SNP rs870729
SNPa Distance to rs870729 p Value r2case
b D0case
b r2control
b D0control
b D0 Ratioc
rs2992950 853628 0.002274 0.001 0.106 0 0.014 7.57
rs17080523 849341 0.002406 0 0.092 0 0.002 46.00
rs7329467 62457 6.87E-08 0.117 0.495 0.003 0.071 6.97
rs7984378 47459 0.003742 0.015 0.234 0.002 0.084 2.79
rs2313475 31103 0.00413 0.056 0.257 0 0.027 9.52
rs3751385 18923 1.50E-09 0.744 0.889 0.673 0.843 1.05
rs6490527 2550 0.006606 0.211 1 0.265 1 1.00
rs7319601 56340 0.007069 0.026 0.237 0.009 0.166 1.43
rs9509124 59891 0.005835 0.031 0.256 0.01 0.172 1.49
rs9315439 63701 0.000129 0.051 0.235 0 0.007 33.57
rs7992230 66438 0.001725 0.081 0.663 0.036 0.5 1.33
rs1537788 82693 4.71E-05 0.075 0.373 0.033 0.277 1.35
rs9285110 85313 9.38E-05 0.057 0.369 0.03 0.305 1.21
rs1547721 86181 0.004168 0.075 0.639 0.037 0.51 1.25
rs7327522 89416 0.007661 0.035 0.261 0.001 0.048 5.44
rs4769989 93031 0.002192 0.04 0.313 0.001 0.048 6.52
rs7323752 95958 0.002151 0.04 0.323 0.002 0.084 3.85
rs7323769 95987 0.00054 0.043 0.409 0.008 0.202 2.02
rs1953516 99267 0.00039 0.049 0.447 0.01 0.236 1.89
rs7337231 114739 0.002022 0.028 0.309 0.009 0.204 1.51
rs9509167 125622 0.001591 0.016 0.215 0.008 0.173 1.24
rs12868032 128169 0.003955 0.017 0.211 0.006 0.151 1.40
rs9550637 130648 0.007389 0.029 0.221 0.002 0.06 3.68
a SNPs selected for constructing long-range haplotypes are marked in bold font.
b r 2 and D0 measure correlation between each SNP and the index SNP rs870729.
c D0 ratio is defined as D0case / D0control.diseases (such as type 2 diabetes [MIM 125853]). Neverthe-
less, because hundreds of causal variants have been docu-
mented in many studies sequencing this region (Con-
nexin-deafness database), the knowledge regarding the
known causal variants helps us test our method of identi-
fying them by sequencing. We previously performed
a GWAS on 418 cases and 6892 control subjects, and we
identiﬁed genome-wide signiﬁcant associations within
the GJB2-GJB6 locus, the most signiﬁcant tag SNP being
rs870729 (MAF ¼ 19%, p ¼ 3.4 3 1011, OR ¼ 1.7).16
Here, we surveyed the whole-genome genotype data to
search for loci with evidence of long-range haplotypes in
cases, using a simple summary statistic called the median
D0case / D0control ratio. In essence, the summary statistic eval-
uates differences in LD patterns in cases compared to
controls in a given locus surrounding an index SNP (the
most signiﬁcant SNP at a locus). A locus on 10q25.1
showed the strongest evidence of long-range haplotypes
(with rs7085286 as index SNP, association p ¼ 2.1 3
105, median D0case / D0control ratio ¼ 3.3). The GJB2-GJB6The Amelocus (with rs870729 as index SNP) showed the second
strongest evidence of long-range haplotypes (median
D0case / D0control ratio ¼ 1.8). At the GJB2-GJB6 locus, for
23/23 (100%) of the SNPs, we observed a higher D0 value
in cases than in controls (Table 2), and some of the stron-
gest D0 ratios were observed 850 kb away from the index
SNP across multiple LD blocks, supporting the assumption
that a long-range haplotype is indeed present in cases.
Next, we obtained sequencing data on the GJB2 locus
for a set of 329 cases, whose DNA were available for
sequencing. On the basis of well-documented annotations
of mutations, a total of 19 unique causal variants were
observed. Not surprisingly, we found that 37 cases carry
the 35delG mutation, which has an MAF of 8.2% in cases,
far higher than the known frequency (1.25%) in controls
of European ancestry.53 Several less frequently observed
causal variants in cases include M34T (MAF ¼ 1.4%),
167delT (MAF ¼ 1.2%), L90P (MAF ¼ 1.1%), V37I (MAF ¼
0.5%), and a GJB6 deletion (MAF ¼ 0.3%), and they
collectively account for 86% of the causal mutations atrican Journal of Human Genetics 86, 730–742, May 14, 2010 737
Table 3. A List of Haplotypes and Their Estimated Frequencies in Hearing Loss Cases and Controls
Haplotypea Frequency (Cases) Frequency (Controls) Odds Ratio p Valueb Cases with 35delG Cases with 167delT
212121121112 0.053 0.008 6.8 0 88% (28/32)
212121121111 0.010 0.001 12.7 4.73E-05 67% (4/6)
211111121112 0.010 0.002 4.08 0.00608
211121121112 0.015 0.006 2.55 0.00967
121212212221 0.018 0.009 2.08 0.0212
211111221112 0.009 0.003 2.81 0.0276
121112212221 0.014 0.008 1.77 0.111
211112221112 0.021 0.016 1.35 0.267 38% (5/13)
211122121112 0.015 0.011 1.37 0.342
211122212211 0.009 0.007 1.27 0.482
211112222111 0.011 0.009 1.23 0.519
a Best-guess haplotypes with > 1% frequency in cases and with an OR > 1 are shown; 1 and 2 in the haplotype refers to the A and B alleles for SNPs listed in Table
2, per Illumina’s TOP/BOT allele designation.
b p value is calculated by Fisher’s exact test.the GJB2-GJB6 locus in our data. Interestingly, 35delG is
in high LD with the tag SNP rs870729 (D0 ¼ 0.95). The
other ﬁve causal variants (M34T, 167 delT, L90P, V37I,
GJB6 deletion) are in complete LD with rs870729 (D0 ¼ 1),
though we acknowledge that LD calculation is unstable
when the MAF for one variant is very low. However, it is
clear that the MAF of rs870729 is far higher than that of
any causal variants, so if we had sequenced only a handful
of control subjects for variant discovery, we would not ﬁnd
many of these rare causal variants. Because we cannot put
these causal variants into custom arrays or use them in
imputation, we would not identify them by traditional
ﬁne-mapping efforts.
We then focused onwhether we can conﬁdently identify
a subset of cases carrying the 35delG mutation, using SNP
genotype data alone. We set a D0case / D0con > 2 threshold,
and we selected 11 SNPs (bold font in Table 2) for phasing
long-range haplotypes by fastPHASE45 and comparing the
best-guess haplotype frequencies in cases versus controls
(Table 3). The most striking difference was observed for
a long-range haplotype that has an allele frequency of
0.8% in controls but 5.3% in cases, suggesting that it
may tag a causal allele with major effects. By comparison
with the resequencing data, we found that 28/32 (88%)
of the cases carrying this haplotype also have the 35delG
mutation, indicating a high positive predictive value of
this haplotype for the presence of 35delG. The allele fre-
quency of 35delG is 66% in these 32 cases, suggesting
that sequencing a few of these cases can easily identify
the causal variants. In addition, the case-selection method
has high speciﬁcity, because only 0.8% of the controls
carry this long-range haplotype, and some of them prob-
ably do carry the 35delG mutation. Our results thus
provide strong evidence supporting the validity and effec-
tiveness of the case-selection approach.738 The American Journal of Human Genetics 86, 730–742, May 14,Several additional haplotypes also show enrichment as
being overrepresented in cases versus controls, so we inves-
tigated whether they were tagging additional rare variants.
We found that the second haplotype, despite being rare,
actually also tagged the 35delG causal variant, with 4/6
(67%) of the cases predicted to harbor this haplotype
carrying the 35delG variant. Additionally, we also found
that another haplotype, with a frequency of 1.6% in
controls and 2.1% in cases, predicts the presence of the
167delT mutation, as 5/13 (38%) of the cases with this
haplotype also carry a 167delT mutation. No other haplo-
types seem to be tagging other causal variants, such as
M34T, L90P, or V37I. In practice, given limited sequencing
resources, some researchers may choose to sequence one
best-candidate haplotype ﬁrst, but other haplotypes should
also be surveyed to ﬁnd amore comprehensive ensemble of
causal variants. Altogether, if we had sequenced a dozen
cases carrying a few speciﬁc long-range haplotypes, we
could have easily identiﬁed at least one causal mutation
for hearing loss in the GWAS data. It is likely that diseases
that are more complex than hearing loss may not be as
straightforward to analyze, but as an extreme example,
the hearing loss data suggest the potential utility of enrich-
ing cases to discover causal variants.Discussion
In the current study, we illustrated the potential effect-size
distortion of causal variants in GWAS and the potential
underestimation of heritability explained for loci detected
by GWAS, through the analysis of a well-known locus
for Crohn disease. We then proposed a case-selection
approach that enriches samples likely to carry long-range
haplotypes containing causal alleles, and we demonstrated2010
the effectiveness of this approach on a simulated data set
and on a real data set with resequencing data. There are
several caveats related to the three major aspects of this
study:
When an association signal on a common tag SNP was
due to one or more rare variants, our simple theoretical
calculation and real-data analysis conﬁrmed that tag
SNPs may underestimate the true effect sizes of causal vari-
ants in GWAS. However, we stress several issues here in
the interpretation of effect sizes. First, the magnitude of
underestimation depends on the allele frequency of the
synthetic causal marker rather than each individual causal
variant, because the tag SNP measures the combined
effects of several causal variants. Second, given that rare
mutations have emerged relatively recently, the casual
variants in the same gene may vary between ethnicity
groups (for example, causal variants in PCSK9 for low-
density lipoprotein cholesterol levels differ completely
between European Americans and African Americans21).
Therefore, in the presence of synthetic association, a tag
SNP may be associated with the same phenotype in
different ethnicity groups, but the effect sizes could differ
substantially or even be in opposite directions, because
the tag SNP may tag different sets of causal variants. Third,
synthetic association could result in distortion of disease
models, whereas causal variants with dominant or reces-
sive effects could manifest as if they increase disease risk
in a somewhat multiplicative fashion. Finally, synthetic
association does not exclude the possibility that rare vari-
ants with strong effects and common variants withmodest
effects coexist at the same locus. Many disease loci (for
example, KCNJ11 for type 2 diabetes54) were discovered
through study of a few families with extreme or Mendelian
form of the disease, whereas common variants with lower
penetrance were later discovered at the same loci (for
example, the E23K mutation in KCNJ11 has an OR value
less than 255 and is functionally validated as potentially
causal56).
If a susceptibility locus is subject to synthetic associa-
tion, how can we estimate the magnitude and recover
the missing heritability? In the absence of resequencing
data at the locus on many subjects, this question cannot
be answered directly by association results from GWAS
alone, because we do not know a priori the distribution
of frequencies and effect sizes of causal variants at the
locus. However, for many diseases, it is feasible to dig out
old linkage results on the same locus: although the LOD
scores may not reach stringent criteria for statistical signif-
icance, the identity-by-descent sharing statistics at the
locus can be used to estimate heritability explained.34 If
several linkage studies are examined and they show largely
consistent results, one could in principle recover the true
heritability explained by the locus from linkage statistics.
Therefore, old linkage data sets could be very useful for
interpreting new GWAS results. This idea remains to be
tested, after large-scale sequencing data on many subjects
is available for some disease loci.The AmeMany current ﬁne-mapping efforts aim at ﬁrst se-
quencing a small group of subjects to discover variants,
because we do not yet have a comprehensive catalog of
genetic variants in humans in diverse ethnicity groups.
Our study highlights the importance of the 1000 Genomes
Project to catalog rare variants, but we caution that some
ethnicity-speciﬁc variants that contribute to risk could be
well below the threshold of detection in the 1000
Genomes Project. Additionally, our study also suggests
the need to generate high-coverage sequencing data, so
that we can have reasonably accurate estimates of allele
frequencies of some rare variants in control populations.
This is because most sequencing studies of candidate loci
will generate high levels of coverage (303 or more) to
ensure accurate genotyping, but if only 4–63 coverage is
available on the 1000 Genomes Project data, we could
not determine whether a given rare variant is overrepre-
sented in cases, unless we sequence our own controls at
high coverage as well. Furthermore, imputation algorithms
may work less well for rare variants than for common
ones for low-coverage sequencing data. Therefore, the
availability of high-coverage data from the 1000 Genomes
Project will reduce the need of individual investigators to
sequence controls, so that valuable sequencing resources
can be focused on more cases for improving the power of
ﬁnding associated variants.
We also acknowledge that a case-only design for rese-
quencing could potentially induce false positives (inﬂated
type I error); that is, many of the discovered variants from
sequencing could be spuriously associated with disease.
This issue has already been extensively discussed before.57
Therefore, researchers should not utilize custom arrays
only on the original GWAS data set to infer causal variants.
Instead, just like a replication study on GWAS, a custom
array with candidate causal variants should always be
tested in independent sample sets for assessment of their
true effects. Finally, functional validation is the ultimate
answer to the causality of candidate causal variants, and
it is required for the biological understanding of disease-
locus relationships.
In conclusion, in those instances when the association
signals detected in GWAS are due to the presence of
multiple causal variants, researchers need to take caution
in interpreting the true effect sizes and heritability ex-
plained by the causal variants. With the successful identiﬁ-
cation of hundreds of disease-susceptibility loci, many
research groups have now started to apply ﬁne-mapping
experiments to identify causal alleles, mostly by designing
custom ﬁne-mapping arrays, which require large amounts
of investments andhumanendeavor. These typesof custom
arrays, which in design may miss many rare variants
(because of the way in which variants were ascertained),
cannot interrogate the full spectrum of causal alleles. On
the other hand, it is important to consider the possibility
of ‘‘synthetic association’’ when designing ﬁne-mapping
experiments, in order to gain at least empirical data
supporting the comparative effectiveness between customrican Journal of Human Genetics 86, 730–742, May 14, 2010 739
SNP panels versus targeted long-range resequencing in
ﬁnding causal variants. It is also a priority to develop
methods for selecting extreme cases for resequencing
studies and performing subsequent association tests on
rare variants.57–59 Ultimately, resequencing a few well-phe-
notyped cases, supplemented with the deep-sequencing
data from the 1000 Genomes Project, may turn out to be
more cost efﬁcient and may provide more insights than
what could be gleaned from traditional ﬁne-mapping
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